Werewolf Therapeutics Q4 2024 GAAP EPS $(0.46) Misses $(0.42) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $111M, Expected To Provide Cash Runway Into Q2 Of 2026

Benzinga
03-11

Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.42) by 9.52 percent. This is a 39.39 percent decrease over losses of $(0.33) per share from the same period last year.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

no data

沒有相關數據

如果下載按鈕點擊無跳轉,請點擊右上角菜單選擇 “在瀏覽器打開”